Lipid profiles in major depression, both with and without metabolic syndrome: associations with suicidal behaviors and neuroticism.

ingentiumby ingentium

In Major Depressive Disorder Literature.

Publication date: Apr 15, 2025

Significant associations exist between major depressive disorder (MDD), metabolic syndrome (MetS), and cardiovascular disease, potentially attributable to heightened atherogenicity. This study aimed to ascertain if MDD, depression severity, suicidal behaviors, and neuroticism associate with elevated pro-atherogenic indices and reduced anti-atherogenic indices, including a reverse cholesterol transport (RCT) index. This study comprised 34 healthy controls and 33 MDD patients without MetS, and 35 controls and 31 MDD patients with MetS. It assessed total cholesterol (TC) and free cholesterol (FC), high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), triglycerides (TG), apolipoprotein (ApoA), ApoB, cholesterol esterification rate, and a RCT composite. No significant associations between MDD and lipids were seen in the total study group that combined individuals with and without MetS. In individuals devoid of MetS, MDD is significantly correlated with (a) elevated FC, TG, ApoB, Castelli risk index 1, and ApoB/ApoA, and (b) diminished HDLc, ApoA, and RCT index. In individuals without MetS, there are notable correlations between the severity of depression, suicidal tendencies, neuroticism, and ApoB/ApoA, Castelli risk, and RCT indices. The link between lipids and MDD features cannot be adequately estimated by combining participants with and without MetS. It should be examined in a study sample that excludes subjects with MetS. The depression phenome, suicidal behaviors, and neuroticism correlate with diminished RCT and heightened atherogenicity, which are likely implicated in the pathophysiology of MDD. Increased atherogenicity and lowered RCT may represent novel drug targets for the treatment and prevention of MDD, neuroticism, and suicidal behaviors.

Open Access PDF

Concepts Keywords
Cholesterol Atherogenicity
Mets Cardiovascular disease
Pro Lipids
Psychiatry Major depression
Triglycerides Mood disorders
Reverse cholesterol transport

Semantics

Type Source Name
disease MESH depression
disease MESH metabolic syndrome
disease MESH neuroticism
disease MESH major depressive disorder
disease MESH cardiovascular disease
drug DRUGBANK Cholesterol
disease MESH Suicide
pathway REACTOME Reproduction
disease MESH syndrome
disease MESH Mood disorders
drug DRUGBANK Coenzyme M
disease MESH abnormalities
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease MESH diabetes mellitus
disease MESH obesity
disease MESH dyslipidemia
disease MESH atherosclerosis
disease MESH comorbidity
disease MESH anxiety
disease MESH suicidal ideation
disease MESH multiple sclerosis
disease MESH stroke
disease MESH Parkinson disease
pathway KEGG Parkinson disease
disease MESH epilepsy
disease MESH brain tumors
disease MESH schizophrenia
disease MESH psychosis
disease MESH autism
disease MESH bipolar disorder
disease MESH borderline personality disorder
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH arthritis
disease MESH chronic obstructive pulmonary disease
disease MESH chronic kidney disease
disease MESH psoriasis
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Pomalidomide
drug DRUGBANK Astaxanthin
drug DRUGBANK Glipizide
drug DRUGBANK Metformin
drug DRUGBANK Amlodipine
drug DRUGBANK Enalapril
drug DRUGBANK Prazosin
drug DRUGBANK Liraglutide
disease MESH dysthymia
disease MESH anxiety disorders
disease MESH post traumatic stress disorder
disease MESH agoraphobia
disease MESH social phobia
disease MESH panic disorder
disease MESH privacy
disease MESH high blood pressure
drug DRUGBANK Pidolic Acid
disease MESH affective symptom
drug DRUGBANK L-Phenylalanine
pathway REACTOME Translation
drug DRUGBANK Erythropoietin
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Glycerin
drug DRUGBANK Water
drug DRUGBANK Medical air
disease MESH marital status
disease MESH infection
disease MESH unemployment
drug DRUGBANK Sertraline
drug DRUGBANK Trazodone
drug DRUGBANK Venlafaxine
drug DRUGBANK Paroxetine
drug DRUGBANK Agomelatine
drug DRUGBANK Mirtazapine
disease MESH Covid 19
drug DRUGBANK Simvastatin
drug DRUGBANK Losartan
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Sodium lauryl sulfate
disease MESH unstable angina
disease MESH oxidative stress
drug DRUGBANK Piroxicam
disease MESH atheroma
disease MESH death
pathway REACTOME Apoptosis
pathway KEGG Platelet activation
disease MESH inflammation
disease MESH recurrence
drug DRUGBANK Esomeprazole
drug DRUGBANK Etoperidone
drug DRUGBANK Trestolone
disease MESH Cognitive Impairment
disease MESH Dementia
drug DRUGBANK Copper
drug DRUGBANK Calcium
disease MESH mental disorders
disease MESH cardiovascular risk
disease MESH nitrosative stress
disease MESH cancer
drug DRUGBANK Carboxyamidotriazole
disease MESH adverse childhood experiences
drug DRUGBANK Hydrocortisone
drug DRUGBANK Testosterone
disease MESH tic
disease MESH coronary artery disease
disease MESH hypomania
disease MESH Hypertriglyceridemia
drug DRUGBANK Rosuvastatin
disease MESH metabolic diseases
disease MESH acute phase response

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *